^
Association details:
| Biomarker: | AR positive |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Balversa (erdafitinib) (FGFR inhibitor, FGFR1 inhibitor, FGFR4 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor) + zoligratinib (Debio 1347) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer
Published date:
10/05/2023
Excerpt:
In vitro/ex vivo analysis of erdafitinib and CH5183284 demonstrated robust and moderate growth suppression of ARPC, respectively.
DOI:
10.1002/pros.24630
